Related Experiment Videos
Prostate-specific antigen: effect of pelvic irradiation
1Department of Radiation Oncology, Klinik für Strahlentherapie und Radiogische Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany. stephan.gripp@uni-duesseldorf.de
Radiology
|June 1, 2000
Summary
Pelvic irradiation initially increases serum prostate-specific antigen (PSA) levels, but long-term radical radiation therapy impairs PSA production. PSA reference concentrations may need adjustment post-treatment.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
- Pelvic irradiation is a treatment modality for various cancers, including anal and rectal cancers, potentially affecting the prostate.
Purpose of the Study:
- To investigate the impact of pelvic irradiation on serum PSA levels in patients treated for anal and rectal cancer.
Main Methods:
- Serum PSA levels were measured in 33 patients before, during, and after pelvic irradiation.
- Patients received varying doses of radiation (50.4 Gy or 25.0 Gy).
- PSA data were analyzed using the Wilcoxon rank test, with a mean follow-up of 15.7 months.
Main Results:
- Serum PSA levels showed a significant 3.7-fold increase during the first 3 weeks of radiation therapy (P =.02).
- PSA levels returned to pretreatment values by the end of the 7-week therapy course.
- Long-term follow-up revealed a sustained decrease in PSA levels to 77% of pretreatment values (P =.04).
Conclusions:
- Pelvic irradiation initially elevates serum PSA levels, with release influenced by radiation duration rather than accumulated dose.
- Radical radiation therapy leads to long-term impairment of PSA production.
- Current PSA reference concentrations may require adjustment for patients who have undergone radical radiation therapy.